RxDoctor Payments Data

Elizabeth Armstrong

Psychiatric/Mental Health · Madison, WINPI 1780033431

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,754 of the $2,692 with a category attached, or 65.2%. 8 manufacturers reported payments, led by Neuronetics, Inc. at 57.8% of the total. Reporting peaked in 2024 at $1,696 and has fallen 96.0% since, to $68 in 2025.

$2,692in general payments, 2019–2025

Across 30 payments — averaging $89.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$2K
  • AbbVie$526
  • Alkermes, Inc.$428
  • E.r. Squibb & Sons, L.L.C.$68
  • Axsome Therapeutics, Inc.$64
  • Supernus Pharmaceuticals, Inc.$18
  • plus $33 from 2 others

What the payments were for

  • Travel & lodging$93835%
  • Food & beverage$1,75465%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,692 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$27,904
Medicare patients
29
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl52$59,797
LybalviOlanzapine/Samidorphan Malate24$46,511
FanaptIloperidone13$22,099
BelsomraSuvorexant14$6,218
VyvanseLisdexamfetamine Dimesylate14$5,204
Aripiprazole115$4,768
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$4,213
DayvigoLemborexant12$3,734
Atomoxetine Hcl32$3,157
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine23$2,304
Propranolol Hcl ErPropranolol Hcl57$1,538
Trazodone Hcl70$1,108
Vilazodone Hcl18$986
Quetiapine Fumarate52$793
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl11$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$526$59,79752 claims
Alkermes, Inc.Lybalvi$428$46,51124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →